Advanced glycation end-product crosslink (AGE crosslink)

Advanced glycation end-product crosslinks are covalent bonds formed between proteins—most notably collagen and elastin—through a nonenzymatic reaction with sugars in a process called glycation or the Maillard reaction[1][3][5]. These sugar-derived links accumulate over time in tissues, causing them to become stiffer and less elastic. This increased rigidity contributes to age-related changes such as hypertension, reduced cardiac function, kidney dysfunction, cataracts, and other degenerative conditions[3][4]. The accumulation of these crosslinks is accelerated in diabetes due to chronically high blood glucose levels. AGEs themselves are not receptors or enzymes but rather chemical modifications that alter the structure and function of long-lived proteins. They can be measured as biomarkers for aging or chronic disease risk but are not considered classical therapeutic targets like receptors or enzymes. However, drugs such as alagebrium (ALT‑711) have been developed to break these pathological protein-protein links in an effort to restore tissue flexibility and improve organ function[2][4]. The term "advanced glycation end-product crosslinks" refers specifically to the structural modifications caused by AGEs rather than a discrete molecular target suitable for direct drug binding. Therefore, it is not considered a canonical therapeutic target but rather a pathological feature addressed by certain pharmacological strategies. AGEs also interact with specific cellular receptors such as RAGE (receptor for advanced glycation end products), which mediates some downstream inflammatory responses when bound by AGEs; however, "advanced glycation end-product crosslink" itself is not synonymous with this receptor nor any single protein entity[1].

Other names

Advanced glycation end productsAGEssugar crosslinksprotein-sugar crosslinks

Cross-link breaker (e.g., ALT-711 breaks AGE-mediated protein-protein bonds)[4]